Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
JAK3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAK3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JAK3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JMJD7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JMJD7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JMJD7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JAK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITPKC Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITPKC Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ITPKC sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITPKA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITPKA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ITPKA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JAK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ITK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITPKB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITPKB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ITPKB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IP6K3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IP6K3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IP6K3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →